1924 Results for "

Met

" in MedChemExpress (MCE) Product Catalog:
Products (1924)

1924 Results for "Met" in MCE Product Catalog:

268
268 Publications Verification
Cat. No.: HY-P0175
CAS No.: 1236188-16-1
Synonyms: 740YPDGFR; PDGFR 740Y-P
Target:  

PI3K Autophagy

Research Areas:  

Cancer

740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
loading...
    loading...
148
148 Cited Publications
Cat. No.: HY-A0190
CAS No.: 17650-98-5
Synonyms: Ceruletide; Cerulein; FI-6934
Caerulein is a decapeptide and a potent cholecystokinin receptor agonist. Caerulein is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .
loading...
    loading...
89
89 Cited Publications
Cat. No.: HY-50878
CAS No.: 877399-52-5
Synonyms: PF-02341066
Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .
loading...
    loading...
89
89 Cited Publications
Cat. No.: HY-50878A
CAS No.: 1415560-69-8
Synonyms: PF-02341066 hydrochloride
Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .
loading...
    loading...
72
72 Cited Publications
Cat. No.: HY-13443
CAS No.: 141758-74-9
Purity:  99.95%
Synonyms: Exenatide
Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .
loading...
    loading...
72
72 Cited Publications
Cat. No.: HY-13443A
CAS No.: 914454-01-6
Purity:  99.91%
Synonyms: Exenatide acetate
Exendin-4 acetate (Exenatide acetate) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin-4 acetate mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin-4 acetate inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin-4 acetate reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin-4 acetate can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .
loading...
    loading...
59
59 Cited Publications
Cat. No.: HY-13016
CAS No.: 849217-68-1
Purity:  99.96%
Synonyms: XL184; BMS-907351
Research Areas:  

Cancer

Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .
loading...
    loading...
58
58 Cited Publications
Cat. No.: HY-12044
CAS No.: 1140909-48-3
Purity:  99.90%
Synonyms: XL184 S-malate; BMS-907351 S-malate
Target:  

VEGFR Apoptosis

Research Areas:  

Cancer

Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-P0128
CAS No.: 131602-53-4
Synonyms: Amyloid beta-peptide (25-35); Aβ25-35; β-Amyloid peptide (25-35)
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-P0128A
CAS No.: 131602-53-4
Synonyms: Amyloid beta-peptide (25-35), HFIP-treated; Aβ25-35, HFIP-treated; β-Amyloid peptide (25-35), HFIP-treated
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .
loading...
    loading...
46
46 Cited Publications
Cat. No.: HY-P0264
CAS No.: 133514-43-9
Synonyms: Avexitide
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .
loading...
    loading...
46
46 Cited Publications
Cat. No.: HY-P0264A
CAS No.: 2051593-46-3
Synonyms: Avexitide acetate
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .
loading...
    loading...
45
45 Cited Publications
Cat. No.: HY-P0151
CAS No.: 213546-53-3
Target:  

NF-κB

Research Areas:  

Inflammation/Immunology

SN50 is a cell permeable inhibitor of NF-κB translocation.
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-P0017
CAS No.: 9087-70-1
Aprotinin is a bovine pancreatic trypsin inhibitor (BPTI) inhibitor which inhibits trypsin and chymotrypsin with Kis of 0.06 pM and 9 nM, respectively.
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-P0319
CAS No.: 402750-12-3
Research Areas:  

Others

3X FLAG peptides are FLAG-tagged peptides containing three repeats of the Asp-Tyr-Lys-Xaa-Xaa-Asp motif. 3X FLAG peptide can be used for protein separation and purification, and competitive elution with target proteins.
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-P0319A
Target:  

Inhibitory Antibodies

Research Areas:  

Others

3X FLAG peptide TFA is a FLAG-tagged peptide containing three repeats of the Asp-Tyr-Lys-Xaa-Xaa-Asp motif. 3X FLAG peptide TFA can be used for protein separation and purification, and competitive elution with target proteins.
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-P0201
CAS No.: 33507-63-0
Synonyms: Neurokinin P
Substance P (Neurokinin P) is a CNS-penetrant neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R).
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-P0201A
CAS No.: 148470-19-3
Synonyms: Neurokinin P TFA
Substance P TFA (Neurokinin P TFA) is a CNS-penetrant neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R) .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-13404
CAS No.: 1029712-80-8
Purity:  99.75%
Synonyms: INC280; INCB28060
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-13404A
CAS No.: 1197376-85-4
Synonyms: INC280 dihydrochloride; INCB28060 dihydrochloride
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
loading...
    loading...